Copeptin in Differentiation of Polyuria and Polydipsia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01056887|
Recruitment Status : Completed
First Posted : January 26, 2010
Last Update Posted : April 25, 2011
The differential diagnosis of patients with polyuria/ polydipsia is often complex, but important for the therapeutic strategy.
Challenging is in particular the clinical differentiation between patients with a partial Diabetes insipidus centralis and patients with primary polydipsia as underlying disease, because both groups are associated with similar urinary osmolalities.
The determination of plasma arginine vasopressin is unusual in this context, since measurement of AVP is not reliably.
C-terminal ProVasopressin (copeptin) is secreted stoichiometrically with AVP from the neurohypophysis, but has a longer half life in the circulation, and is thus easier to measure.
Therefore, the investigators will analyze in that study the diagnostic utility of plasma copeptin in the differential diagnosis of polyuria and polydipsia.
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||50 participants|
|Study Start Date :||March 2008|
|Actual Primary Completion Date :||November 2010|
|Actual Study Completion Date :||November 2010|
|Primary Polydip, D. insipidus|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01056887
|Univ Hospital Wuerzburg|
|Wuerzburg, Bavaria, Germany, 97080|